Therefore, a further development of this combination regimen in patients that already received anthracyclines and taxanes in the early setting might be envisioned, especially in PD-L1 negative TNBC and BRCA-wild type HER2-negative BC, even more in cases of high tumor burden and when a rapid tumor shrinkage is required. The gene discussed is ERBB2; the disease is neoplasm.